Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Norovirus GI.1 major capsid protein (VP1) is the principal structural protein forming the icosahedral capsid of norovirus, which causes a significant proportion of human acute viral gastroenteritis cases worldwide[1][2][4][5][7]. VP1 is encoded by ORF2 and forms 90 stable dimers, totaling 180 monomers per virion, with each monomer comprising distinct domains: a conserved shell (S) domain and a highly variable protruding (P) domain, further divided into P1 and P2 subdomains[1][2][5][7]. The P domain mediates binding to host cellular receptors, namely histo-blood group antigens (HBGA), which are essential for virus entry and tropism[6][7]. VP1 presents key epitopes for neutralizing antibodies, making it a focus of vaccine and antiviral therapeutic development[5][6]. High conformational flexibility of the P domain contributes to immune evasion and adaptability, presenting challenges for vaccine efficacy but also opportunities for inhibition by nanobodies and small molecule HBGA mimics[3][5][6].
Blockade of virus binding to histo-blood group antigens (HBGA)[6] Capsid destabilization or aggregation via antibody binding[6]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Norovirus GI.1 major capsid protein (VP1).